Chronic Obstructive Pulmonary Disease (COPD) Treatment Market (Drug Class: Combination Therapy, Corticosteroids, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Bronchodilators, Others; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2030

Description

Innovations in Combination Therapy to Dominate COPD Treatment Market

The chronic obstructive pulmonary disease treatment market is projected to be valued at ~US$ 26.2 billion in the year 2027. The high prevalence of chronic obstructive pulmonary disease (COPD) and the need for improved treatment options are catalyzing market growth.

To meet the needs of patients, healthcare companies in the COPD treatment market are developing efficacious treatment options in combination therapy. Revenue of combination therapy was valued at ~US$ 9.6 billion in 2018; the highest amongst all the drug classes in the chronic obstructive pulmonary disease treatment market.

With increased research & development, healthcare companies are innovating new triple combination therapies. For instance, in June 2019, AstraZeneca — an English-Swedish multinational pharmaceutical company, announced the approval of Breztri Aerosphere — a pressurized metered dose inhaler with built-in triple combination therapy for patients suffering from moderate to severe COPD in Japan. Stakeholders in the chronic obstructive pulmonary disease treatment market are running continuous clinical trials to meet the primary endpoints of the disease.

Dual and Triple Therapies Minimize Moderate and Severe Exacerbations

With ongoing developments in the chronic obstructive pulmonary disease treatment market, healthcare companies are weighing the responses and combination of therapies in patients. As such, there is a strife between the credibility of dual combination therapy and long acting bronchodilators for treatment in COPD patients.

To achieve greater effectiveness of therapies in the chronic obstructive pulmonary disease treatment market, manufacturers have integrated combinations of bronchodilators to treat patients with moderate to severe COPD. This includes the combination of long acting beta agonist (LABA) with long acting muscarinic antagonist (LAMA). Thus, the LAMA and LABA group of inhalers are considered safe and effective in COPD patients.

Also, triple therapy has shown better outcome in patients as compared to single-agent LAMA monotherapy in the COPD treatment market. Compared with LAMA monotherapy, triple therapy helps to drastically reduce moderate or severe exacerbations. Thus, healthcare companies are making significant improvements to enhance triple therapy against dual therapy LABA/LAMA.

Improved Bronchodilators Reduce Reversibility in Patients

Stakeholders in the chronic obstructive pulmonary disease treatment landscape are developing methods to reduce emphysema and the mortality rates of patients. This has instigated the need for combined bronchodilator response (BDR) in patients. Revenue of bronchodilators in the COPD treatment market is estimated to reach a value of ~US$ 5.5 billion by 2027; the second-highest amongst all drug classes. This is why, healthcare professionals are taking regular follow-ups on patients with combined-BDR. However, the results in combined-BDR are associated with greater frequency of exacerbations and symptoms of asthma. Thus, healthcare companies are increasing research to identify patients with asthma-COPD overlaps, and developing treatment alternatives that result in improved outcomes.

Studies published in the European Respiratory Journal stated that, bronchodilator reversibility might not distinguish asthma from COPD. It was also found that, the prevalence of bronchodilator reversibility was higher in patients with COPD than in asthma patients. Thus, with the help of bronchodilator response testing, healthcare companies are developing improved prebronchodilators that minimize the adverse effects in patients.

chronic obstructive pulmonary disease treatment market segmentation

Stuck in a neck-to-neck competition with other brands? Request a custom report on “Chronic Obstructive Pulmonary Disease (COPD) Treatment Market”

Analysts’ Viewpoint on COPD Treatment Market

The chronic obstructive pulmonary disease treatment market is anticipated for high growth during the forecast period. Although retail pharmacies dominate more than half of the market share, online pharmacies are expected to experience steady growth in the market. Healthcare companies are introducing digital inhalers with built-in sensors for patients suffering from COPD. For instance, in December 2018, Teva Pharmaceutical Industries — a leading Israeli multinational pharmaceutical company, announced the launch of ProAir® Digihaler™ — a digital inhaler with Bluetooth wireless technology for patients with asthma and COPD. However, healthcare companies are developing improved therapies to reduce the reversibility of inhalers in patients. Thus, manufacturers should focus on increasing triple therapy treatment options to effectively minimize exacerbations.

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: Overview

The chronic obstructive pulmonary disease (COPD) treatment market for the historical period of 2017-2018 and forecast period of 2019-2027, increasing burden of chronic obstructive pulmonary disease, rise in geriatric population, and surge in product approvals and launches are expected to boost the global chronic obstructive pulmonary disease treatment market during the forecast period.

According to the report, the global chronic obstructive pulmonary disease treatment market was valued at ~US$ 17.4 Bn in 2018. The COPD treatment market is expected to expand at a CAGR of ~5% from 2019 to 2027.

Increase in Prevalence of Chronic Obstructive Pulmonary Disease: A Key Driver of COPD Treatment Market

Chronic Obstructive Pulmonary Disease (COPD) is a major health concern affecting a large number of people across the globe. The disease burden is rising, thereby increasing the need for COPD management, and this is anticipated to drive the global chronic obstructive pulmonary disease treatment market.

Tobacco smoking could also lead to COPD, as such, boosting the COPD treatment market. The number of adults addicted to smoking has been increasing. Other risk factors include occupation and indoor air pollution. According to the WHO, the primary cause of COPD is exposure to tobacco smoke (either active smoking or passive smoking).

According to an article published by Medscape in April 2019, the prevalence of COPD, worldwide, varies between 7 - 19%. The Burden of Obstructive Lung Disease (BOLD) study found a global prevalence of 10.1%. Men have a pooled prevalence of 11.8%, while it has a prevalence of 8.5% in women. The numbers vary across different regions around the world. Cape Town, South Africa, has the highest prevalence, affecting 22.2% of men and 16.7% of women.

According to a report by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) published in 2018, the prevalence and burden of COPD are projected to increase in the near future, due to continued exposure to COPD risk factors and aging of the world’s population, which is thereby boosting the growth of the chronic obstructive pulmonary disease treatment market. 

Increase in Adoption of Combination Therapy: A Key Driver of COPD Treatment Market

Combination therapy includes LAMA-ICS, LABA-ICS, triple therapy, and other combination drugs, which are anticipated to drive the chronic obstructive pulmonary disease treatment market.

The adoption of combination therapy is increasing, as it is more effective than separate use of bronchodilator and corticosteroid. There has been an increase in the number of patients being successfully treated with combination therapy, who were not showing signs of recovery with bronchodilators or corticosteroids treatments, which is thereby boosting the growth of the COPD treatment market.

Combination therapy is more effective than monotherapy for improving the symptoms and quality of life.

Regulatory authorities such as the FDA, the European Commission, and the Ministry of Health, Labour and Welfare (MHLW), which is a cabinet level ministry of the Japanese government, have approved the use of combination drugs for the treatment of COPD. In November 2018, GlaxoSmithKline plc and Innoviva, Inc. received authorization from the European Commission for the expanded use of once-daily Trelegy Ellipta, the first single inhaler triple therapy indicated for COPD patients who were not adequately treated with dual bronchodilation. These drugs have a longer patent cover, i.e., till 2030, which will lead to high valuation of the chronic obstructive pulmonary disease treatment market.

In April 2019, the FDA approved the combination therapy for COPD maintenance. A fixed-dose combination of long-acting muscarinic antagonist (LAMA) aclidinium bromide (400 mcg) and long-acting beta-agonist (LABA) formoterol fumarate (12 mcg) has been approved by the FDA for the maintenance and treatment of chronic obstructive pulmonary disease.

Increase in the success rate of combination therapy for COPD treatment and recent regulatory approvals have propelled the adoption of combination therapy in COPD management, thereby boosting the growth of the COPD treatment market.

Patent Expiry of Branded Products and Availability of Generic Equivalents Hamper Market

Patents prevent other manufacturers from developing drugs that are being exclusively manufactured by a patent holder. The patent expiry of branded drugs has a significant impact on the pharmaceutical industry.

In case of the COPD treatment market, a few of the players face the threat of patient expiry, which further increases the availability of generic versions of drugs and creates pricing pressure on manufacturers.

Patent expiry declines revenue generated from the sales of branded drugs, and can affect the market share of a company. For instance, Flixotide/Flovent, Advair, and Serevent are major respiratory products manufactured by GlaxoSmithKline, which are now facing patent expiry. This is likely to lead to a decline in sales, thereby affecting the company’s market position. In January 2019, the FDA approved Mylan's Wixela Inhub, the first generic version of Advair Diskus for the treatment of asthma and COPD.

The availability of generic versions of medicines in the market affects the sales of branded drugs in developed regions such as North America and Europe, and causes pricing pressure, as such, restraining the growth of the chronic obstructive disease treatment market.

Global Chronic Obstructive Pulmonary Disease Market: Competition Landscape

This report profiles major players in the global COPD treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments

Prominent players operating in the global chronic obstructive pulmonary disease treatment market include

  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.)
  • CHIESI Farmaceutici S.p.A.
  • Orion Corporation
  • ​Mylan N.V.

Key Questions Answered in the COPD Treatment Market Report

  • What is the scope of growth for companies in the global chronic obstructive pulmonary disease treatment market?
  • What will be the Y-o-Y growth of the global chronic obstructive pulmonary disease treatment market between 2019 and 2027?
  • Will North America continue to remain the most profitable regional market for COPD treatment providers?
  • Which factors will impede the growth of the global chronic obstructive pulmonary disease treatment market during the forecast period?
  • Which are the leading companies in the global COPD treatment market?

Chronic Obstructive Pulmonary Disease Treatment Market – Segmentation 

Drug Class

  • Combination Therapy
  • Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
  • Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
  • Triple Therapy
  • Others
  • Corticosteroids
  • Phosphodiesterase Type 4 Inhibitors
  • Mucokinetics
  • Bronchodilators
  • Long Acting Beta Agonist (LABA)
  • Short Acting Beta Agonist (SABA)
  • Long Acting Muscarinic Antagonist (LAMA)
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENT

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

4. Market Overview

    4.1. Introduction

        4.1.1. Drug Class Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, 2017–2027

        4.4.1. Market Revenue (US$ Mn) Projection

5. Market Outlook

    5.1. Innovative Solutions for COPD Treatment

    5.2. Pipeline Analysis

6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Drug Class 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        6.3.1. Combination Therapy 

            6.3.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

            6.3.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

            6.3.1.3. Triple Therapy

            6.3.1.4. Others

        6.3.2. Corticosteroids

        6.3.3. Bronchodilators

            6.3.3.1. Long Acting Beta Agonist (LABA)

            6.3.3.2. Short Acting Beta Agonist (SABA)

            6.3.3.3. Long Acting Muscarinic Antagonist (LAMA)

        6.3.4. Phosphodiesterase Type 4 Inhibitors

        6.3.5. Mucokinetics

        6.3.6. Others

    6.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by Drug Class 

7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Distribution Channel 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. Online Pharmacies

    7.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by Distribution Channel 

8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Region

        8.2.1. North America 

        8.2.2. Europe 

        8.2.3. Asia Pacific 

        8.2.4. Latin America 

        8.2.5. Middle East & Africa 

    8.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by region

9. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        9.2.1. Combination Therapy 

            9.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

            9.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

            9.2.1.3. Triple Therapy

            9.2.1.4. Others

        9.2.2. Corticosteroids

        9.2.3. Bronchodilators

            9.2.3.1. Long Acting Beta Agonist (LABA)

            9.2.3.2. Short Acting Beta Agonist (SABA)

            9.2.3.3. Long Acting Muscarinic Antagonist (LAMA)

        9.2.4. Phosphodiesterase Type 4 Inhibitors

        9.2.5. Mucokinetics

        9.2.6. Others

    9.3. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Online Pharmacies

    9.4. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        9.4.1. U.S.

        9.4.2. Canada

    9.5. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis 

        9.5.1. By Drug Class 

        9.5.2. By Distribution Channel 

        9.5.3. By Country/Sub-region

10. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        10.2.1. Combination Therapy 

            10.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

            10.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

            10.2.1.3. Triple Therapy

            10.2.1.4. Others

        10.2.2. Corticosteroids

        10.2.3. Bronchodilators

            10.2.3.1. Long Acting Beta Agonist (LABA)

            10.2.3.2. Short Acting Beta Agonist (SABA)

            10.2.3.3. Long Acting Muscarinic Antagonist (LAMA)

        10.2.4. Phosphodiesterase Type 4 Inhibitors

        10.2.5. Mucokinetics

        10.2.6. Others

    10.3. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        10.3.1. Hospital Pharmacies

        10.3.2. Retail Pharmacies

        10.3.3. Online Pharmacies

    10.4. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Russia

        10.4.7. Rest of Europe

    10.5. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis 

        10.5.1. By Drug Class 

        10.5.2. By Distribution Channel 

        10.5.3. By Country/Sub-region

11. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        11.2.1. Combination Therapy 

            11.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

            11.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

            11.2.1.3. Triple Therapy

            11.2.1.4. Others

        11.2.2. Corticosteroids

        11.2.3. Bronchodilators

            11.2.3.1. Long Acting Beta Agonist (LABA)

            11.2.3.2. Short Acting Beta Agonist (SABA)

            11.2.3.3. Long Acting Muscarinic Antagonist (LAMA)

        11.2.4. Phosphodiesterase Type 4 Inhibitors

        11.2.5. Mucokinetics

        11.2.6. Others

    11.3. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        11.3.1. Hospital Pharmacies

        11.3.2. Retail Pharmacies

        11.3.3. Online Pharmacies

    11.4. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis 

        11.5.1. By Drug Class 

        11.5.2. By Distribution Channel 

        11.5.3. By Country/Sub-region

12. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        12.2.1. Combination Therapy 

            12.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

            12.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

            12.2.1.3. Triple Therapy

            12.2.1.4. Others

        12.2.2. Corticosteroids

        12.2.3. Bronchodilators

            12.2.3.1. Long Acting Beta Agonist (LABA)

            12.2.3.2. Short Acting Beta Agonist (SABA)

            12.2.3.3. Long Acting Muscarinic Antagonist (LAMA)

        12.2.4. Phosphodiesterase Type 4 Inhibitors

        12.2.5. Mucokinetics

        12.2.6. Others

    12.3. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        12.3.1. Hospital Pharmacies

        12.3.2. Retail Pharmacies

        12.3.3. Online Pharmacies

    12.4. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis 

        12.5.1. By Drug Class 

        12.5.2. By Distribution Channel 

        12.5.3. By Country/Sub-region

13. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        13.2.1. Combination Therapy 

            13.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

            13.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

            13.2.1.3. Triple Therapy

            13.2.1.4. Others

        13.2.2. Corticosteroids

        13.2.3. Bronchodilators

            13.2.3.1. Long Acting Beta Agonist (LABA)

            13.2.3.2. Short Acting Beta Agonist (SABA)

            13.2.3.3. Long Acting Muscarinic Antagonist (LAMA)

        13.2.4. Phosphodiesterase Type 4 Inhibitors

        13.2.5. Mucokinetics

        13.2.6. Others

    13.3. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        13.3.1. Hospital Pharmacies

        13.3.2. Retail Pharmacies

        13.3.3. Online Pharmacies

    13.4. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        13.4.1. GCC 

        13.4.2. South Africa

        13.4.3. Israel

        13.4.4. Rest of Middle East & Africa

    13.5. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis 

        13.5.1. By Drug Class 

        13.5.2. By Distribution Channel 

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Player – Competition Matrix (By Tier and Size of companies)

    14.2. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share/ranking Analysis By Company (2018)

    14.3. Company Profiles

        14.3.1. AstraZeneca 

            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.1.2. Company Financials

            14.3.1.3. Growth Strategies

            14.3.1.4. SWOT Analysis

        14.3.2. Boehringer Ingelheim International GmbH

            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.2.2. Company Financials

            14.3.2.3. Growth Strategies

            14.3.2.4. SWOT Analysis

        14.3.3. GlaxoSmithKline plc 

            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.3.2. Company Financials

            14.3.3.3. Growth Strategies

            14.3.3.4. SWOT Analysis

        14.3.4. Novartis AG 

            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.4.2. Company Financials

            14.3.4.3. Growth Strategies

            14.3.4.4. SWOT Analysis

        14.3.5. Teva Pharmaceutical Industries Ltd. 

            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.5.2. Company Financials

            14.3.5.3. Growth Strategies

            14.3.5.4. SWOT Analysis

        14.3.6. Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.) 

            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.6.2. Company Financials

            14.3.6.3. Growth Strategies

            14.3.6.4. SWOT Analysis

        14.3.7. CHIESI Farmaceutici S.p.A. 

            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.7.2. Company Financials

            14.3.7.3. Growth Strategies

            14.3.7.4. SWOT Analysis

        14.3.8. Orion Corporation 

            14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.8.2. Company Financials

            14.3.8.3. Growth Strategies

            14.3.8.4. SWOT Analysis

        14.3.9. Mylan N.V.

            14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.9.2. Company Financials

            14.3.9.3. Growth Strategies

            14.3.9.4. SWOT Analysis

Choose License Type

Checkout Inquiry Sample